Vosoritide Injection [Voxzogo]

DRUG2 trials

Sponsors

University of California, San Francisco, BioMarin Pharmaceutical

Conditions

AchondroplasiaMPS IVAMPS VI

Phase 1

Safety and Efficacy of Voxzogo for Growth Deficits in MPS IVA and VI

Active, not recruitingNCT05845749

University of California, San FranciscoMPS IVA, MPS VI

Start: 2023-09-25End: 2029-12-31Updated: 2026-03-10

Phase 2

Study to Evaluate the Efficacy and Safety of BMN 333 Versus Vosoritide in Children With Achondroplasia

RecruitingNCT07441876

BioMarin PharmaceuticalAchondroplasia

Start: 2026-04-01End: 2029-09-01Target: 160Updated: 2026-05-07